1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders

Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders

  • February 2015
  • ID: 2802270

Summary




Based on survey results from 150 rheumatologists, dermatologists, and gastroenterologists in UK, France, Germany, Spain and Italy, Medical Affairs Reputations (EU5): Biosimilar mAbs in Inflammatory Disorders offers insights on how Medical Affairs teams from companies developing and marketing biosimilar anti-TNF monoclonal antibodies (mAbs) can best meet physician needs on various supporting roles. In addition, gain comparative insights on the Medical Affairs teams’ roles from the originator anti-TNF companies.

Using Need-Gap analysis, a proprietary analytics tool to FirstWord, areas of unmet need are identified, which provide valuable guidance on opportunities for corporate and brand positioning, and communication.

With the launch of biosimilar Remicade, and anti-TNF mAb, currently taking place across the major markets of Europe – France, Germany, Italy, Spain, the UK; EU5 – biosimilar mAb developers and companies marketing branded mAbs require solid evidence upon which to base medical affairs’ strategy for their products. Refining performance through smarter delivery, higher quality interaction, and effective communication with rheumatologists, dermatologists and gastroenterologists becomes vital for ensuring optimal performance levels of Medical Affairs teams.







Key Benefits

Review analysis of 150 EU5 rheumatologists/dermatologists/gastroenterologists’ interactions with Medical Affairs teams highlighting good and bad performance, and identifying key areas for improvement
Gain detailed insights on how Medical Affairs teams from originator and biosimilar anti-TNF companies can improve physician satisfaction across a range of key performance attributes
Understand the key areas physicians prefer to interact with Medical Affairs Teams from the originator and biosimilar anti-TNF companies
Identify usage of 5 originator anti-TNFs, and which products are prescribed most
Learn what physicians believe are the most, and least, important attributes of Medical Affairs team engagement, and how these rate across originator and biosimilar anti-TNF companies
Gain insights on how Medical Affairs teams can provide better service to physicians



Key Features
Filled with charts and up-to-the-minute survey analysis, this report offers:

Precise and timely analysis of 150 EU5 rheumatologists/dermatologists/gastroenterologists’ interactions with Medical Affairs teams highlighting good and bad performance and identifying key areas for improvement
Examination of physicians' current touch points with Medical Affairs teams
Key findings regarding the attributes of Medical Affairs teams physicians value most and least
Detailed data broken down by each EU5 country
Need-Gap analysis, a proprietary analytics tool to FirstWord, identifies current unmet needs


Top Takeaways

Insights on the current status of support and interactions with Medical Affairs teams from the originator anti-TNF companies and biosimilar anti-TNF companies
Expectations of support and interactions with Medical Affairs teams from biosimilar anti-TNF companies
Preferred contact frequency, form and other needs from the biosimilar anti-TNF companies


About the Survey
What is Need-Gap Analysis?
This report includes slides that provide Need-Gap analysis, a proprietary analytics tool that identifies areas of unmet need which provide valuable guidance on opportunities for corporate and brand positioning, and communication.

keyfacts.jpgInterviewing Methodology
Data was collected via a 15-minute Internet-based questionnaire.

sampledis.jpgSample Distribution
150 rheumatologists, dermatologists, and gastroenterologists in France, Germany, Spain, Italy and the UK.

Screening Criteria
See at least 20 patients in total in a typical month
Have been in active practice between 3-35 years
Devote at least 50% of time to direct patient care
Prescribed at least one of the listed originator anti-TNFs
Have had an interaction with Medical Affairs teams from at least one of the originator anti-TNF companies in the past 6 months

Originator Anti-TNFs Included in Survey

Cimzia (certolizumab pegol; UCB)
Enbrel (etanercept; Amgen/Pfizer)
Humira (adalimumab; AbbVie)
Simponi (golimumab; Merck & Co.)
Remicade (infliximab; Janssen Biotech/Merck & Co.)



About FirstWord Reports

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Anal Cancer Global Clinical Trials Review, H2, 2018

Anal Cancer Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018

Anal Cancer Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Anal Cancer Global Clinical Trials Review, H2, 2018" provides an overview of Anal Cancer clinical trials ...

Acute Promyelocytic Leukemia Global Clinical Trials Review, H2, 2018

Acute Promyelocytic Leukemia Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018

Acute Promyelocytic Leukemia Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Acute Promyelocytic Leukemia Global Clinical Trials Review, H2, 2018" provides an overview ...

AIDS - Related Cancer Global Clinical Trials Review, H2, 2018

AIDS - Related Cancer Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018

AIDS - Related Cancer Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “AIDS - Related Cancer Global Clinical Trials Review, H2, 2018" provides an overview of AIDS ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on